Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01978236
Title Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications

melanoma

Therapies

Dabrafenib + Trametinib

Dabrafenib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
GSK Investigational Site Pittsburgh Pennsylvania 15232 United States Details
GSK Investigational Site Houston Texas 77030 United States Details
GSK Investigational Site North Sydney New South Wales 2060 Australia Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field